Xilio Development Inc (XLO NASDAQ) stock market data APIs
$9.2391
-0.09(-1%)
as of August 20, 2026
Try our APIs with
free plan!
Xilio Development Inc Financial Data Overview
Price chart is built with
Anychart
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of masked immuno-oncology therapies. The company's pipeline includes XTX501, a bispecific PD-1 / masked IL-2, for patients with metastatic non-small cell lung cancer; Efarindodekin alfa, an investigational, masked IL-12, that is in Phase 2 clinical trial for patients with advanced solid tumors; and Vilastobart, an investigational tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4 monoclonal antibody. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.
Prev. Close
9.2391
Open
9.1451
High
9.2765
Low
9.094
52 wk Range
6.468-12.74
Market Cap
61 919 K
Shares Outstanding
6 580 K
Revenue
64 092 K
EPS
-0.33
Beta
-0.119
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Xilio Development Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Xilio Development Inc data using free add-ons & libraries
Get Xilio Development Inc Fundamental Data
Xilio Development Inc Fundamental data includes:
- Net Revenue: 64 092 K
- EBITDA: -30 030 000
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-08-12
- EPS/Forecast: -0.59
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Xilio Development Inc News
New
3 Small-Cap Biotech Stocks Pairing Rapid Revenue Growth With High Insider Ownership
It can be hard to identify which small-cap biotech stocks will end up in the vast sea of failed trials, and which have the makings of something more viable. The screener behind this article is built t...
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass., July 06, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for peopl...
Xilio Therapeutics Appoints Ben Harshbarger as Chief Legal Officer
WALTHAM, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for peopl...
Cancer Stocks That Are Advancing the Future of Oncology Care
An updated edition of the March 26, 2026, article. The global oncology market is undergoing rapid transformation, driven by rising cancer incidence, aging population and ongoing scientific advances. ...
Get Xilio Development Inc fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
